FLUVESTRANT TEVA 250mg injection solution in pre-filled syringe medication leaflet

L02BA03 fulvestrant • Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-estrogens

Fulvestrant is a medication used to treat advanced breast cancer in postmenopausal women, especially when the disease is hormone-sensitive. It works by blocking estrogen receptors on cancer cells, thereby preventing their growth and multiplication.

Fulvestrant is administered by intramuscular injection, usually once a month, under medical supervision. The dose and treatment schedule are determined by your doctor based on the stage of the disease and response to therapy. It is important to follow the treatment regularly to achieve the best results.

Side effects may include pain at the injection site, fatigue, nausea, bone or joint pain, and hot flashes. In rare cases, allergic reactions or changes in liver function may occur. Any unusual symptoms should be reported to your doctor immediately.

Fulvestrant is an effective option for controlling advanced breast cancer, but it requires careful medical monitoring. Follow your doctor's instructions and do not stop treatment without their approval to ensure the therapy's effectiveness and safety.

General data about FLUVESTRANT TEVA 250mg

Substance: fulvestrant

Date of last drug list: 01-09-2016

Commercial code: W62773001

Concentration: 250mg

Pharmaceutical form: injection solution in pre-filled syringe

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PLIVA HRVATSKA D.O.O. (PLIVA CROATIA LTD.) - CROATIA

Holder: TEVA PHARMACEUTICALS S.R.L. - ROMANIA

Number: 13812/2021/01

Shelf life: 2 years

Pharmaceutical forms available for fulvestrant

Concentrations available for fulvestrant

250mg, 250mg/5ml

Other substances similar to fulvestrant